Atovaquone
- Atc Codes:P01AX06
- CAS Codes:95233-18-4
- PHARMGKB ID:95233-18-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Belgium: Wellvone; France: Wellvone; Germany: Wellvone; Greece: Wellvone; Italy: Wellvone; Netherlands: Wellvone; Poland: Mepron; Portugal: Wellvone; Spain: Wellvone; Sweden: Wellvone; UK: Wellvone.
North America
Canada: Mepron; USA: Mepron.
Drug combinations
Atovaquone and Proguanil
Chemistry
Atovaquone: C~22~H~19~ClO~3~. Mw: 366.84. (1) 1,4-Naphthalenedione, 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-, trans-; (2) 2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone. CAS-95233-18-4 (1993).
Pharmacologic Category
Miscellanous Antiprotozoals. (ATC-Code: P01AX06).
Mechanism of action
May inhibit electron transport in mitochondria inhibiting metabolic enzymes.
Therapeutic use
Treatment and profilaxis of Pneumocystis carinii pneumonia in intolerance to co-trimoxazole. Treatment of Toxoplasma gondii encephalitis. Primary prophylaxis of HIV-infected persons at high risk for developing Toxoplasma gondii encephalitis.
Pregnancy and lactiation implications
Use during pregnancy only if potential benefit outweighs possible risk to the fetus. Caution during lactation.
Unlabeled use
Contraindications
Life-threatening allergic reaction to the drug or formulation.
Warnings and precautions
Absorption may be decreased in diarrhea or vomiting. Use with caution in severe hepatic impairment or in elderly patients (potentially impaired renal, hepatic, and cardiac function).